menu
    • menu

    Company profile for Atriva Therapeutics

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19. Atriva’s lead produc...
    Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Atriva TherapeuticsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Christophstrasse 32, 72072 Tuebingen
    Telephone
    Telephone
    +49 (0) 7071 8597673
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.atriva-therapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/atriva-therapeutics-gmbh/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AtrivaTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Atriva Announces Exclusive Letter Agreement for Reverse Takeover Transaction
    Atriva Announces Exclusive Letter Agreement for Reverse Takeover Transaction

    18 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/18/2744869/0/en/Atriva-Therapeutics-Announces-Exclusive-Letter-Agreement-for-Reverse-Takeover-Transaction-with-Biocure-Technology.html

    GLOBENEWSWIRE
    18 Sep 2023
    Share Share
    Edesa finds a signal in severely ill Covid-19 patients
    Edesa finds a signal in severely ill Covid-19 patients

    21 Sep 2021

    // Elizabeth Cairns EVALUATE

    https://www.evaluate.com/vantage/articles/news/trial-results/edesa-finds-signal-severely-ill-covid-19-patients

    Elizabeth Cairns EVALUATE
    21 Sep 2021
    Share Share
    Atriva Therapeutics begins patient dosing in phase II RESPIRE trial in Covid-19
    Atriva Therapeutics begins patient dosing in phase II RESPIRE trial in Covid-19

    14 Apr 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=137786&sid=2

    PHARMABIZ
    14 Apr 2021
    Share Share
    Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
    Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

    13 Apr 2021

    // DGAP

    https://www.dgap.de/dgap/News/corporate/atriva-therapeutics-doses-first-patient-phase-respire-trial-covid/?newsID=1434547

    DGAP
    13 Apr 2021
    Share Share
    Artiva Biotherapeutics Raises $120 Million in Series B Financing
    Artiva Biotherapeutics Raises $120 Million in Series B Financing

    26 Feb 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210226005084/en

    BUSINESSWIRE
    26 Feb 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search